Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

Circassia failure AstraZeneca deal cover

News and Trends 17 Mar 2017

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to acquire rights from two AstraZeneca products for pulmonary disease. Circassia could not beat the placebo in a Phase III trial for cat allergy last year, which immediately drove its stock down by 65% and led to the halt of clinical […]

March 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

David Sourdive Cellectis interview off the shelf cell therapy 1

Interview 16 Mar 2017

“In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality”

David Sourdive, co-founder of Cellectis, discusses his pioneering work developing off-the-shelf CAR-T for cancer and the future directions of cell therapy. Last week I had the opportunity to attend the World ADOPT Summit and hear from some of the world leaders in cell therapy. There I met David Sourdive, co-founder and EVP Technical Operations at Cellectis, […]

March 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Mar 2017

France Closes in on an HIV Cure by Detecting Cells with Dormant Viruses

French researchers have found a protein only expressed in HIV-infected reservoir cells, paving the way for an HIV cure that completely eliminates the virus. Researchers from the Institut de Génétique Humaine (IGH) at Montpellier University, France, have discovered a protein, CD32a, that is only present on the surface of CD4 T cells infected with dormant HIV. This […]

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Allergan Editas Medicine CRISPR eye disease

News and Trends 15 Mar 2017

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development alliance with the American Editas Medicine, which is on the side of […]

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Mar 2017

Huge Successful €103M IPO for the Next European Leader in Bioplastics

Avantium has gone public and raised €103M on Euronext Amsterdam and Euronext Bruxelles with Sofinnova Partner as the main shareholder. Avantium, a spin-off from Shell, is developing renewable bioplastics made 100% from plant-based materials with the support of big partners such as Coca-Cola or Danone, for which the Dutch biotech is developing sustainable PlantBottles and yogurt cups, […]

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

roche morphosys antibody alzheimers gantenerumab 1

News and Trends 14 Mar 2017

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

After recent late-stage disappointments from Eli Lilly and Merck, Roche and Morphosys are stepping up with two new Phase III trials in Alzheimer’s. Roche just announced plans to start two new Phase III studies in Alzheimer’s with its antibody candidate gantenerumab, initially developed by the German biotech giant MorphoSys. The trials are expected to begin later this year, but Roche […]

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Spain biotech ecosystem Joan Perello Sanifit Joel Jean Mairet Ysios Luis Mora PharmaMar

Interview 14 Mar 2017

Spain’s Biotech Ecosystem is Starting to Rise! Meet the Revolution’s Leaders

I interviewed three of the leaders of Spain’s biotech ecosystem: they all agree that the country is at an inflection point for growth and international recognition. This all started when I realized there’s usually far less biotech news coming our way from my home country, Spain, than from the UK, France or Germany. I decided to […]

March 14, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Mar 2017

You Can Watch Fleming’s Original Penicillin Culture in Oxford!

The Museum of the History of Science in Oxford is hosting an exhibition on the history of penicillin and the current challenges of antibiotic resistance featuring the first culture used to extract the antibiotic. The discovery of penicillin by Alexander Fleming in the early 20th century changed the world of medicine. Antibiotics have saved millions […]

March 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Mar 2017

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

Galapagos and Pharnext will work together to develop low-dose drug combinations that improve drug efficacy and target new indications. Galapagos, the biggest biotech in Belgium, has closed an R&D agreement with the French Pharnext to develop drug combinations of the billion-euro biotech’s drug candidates with already approved drugs. While Pharnext’s focus has been neurodegenerative diseases, the […]

March 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

breath therapeutics sofinnova fundraising

News and Trends 8 Mar 2017

German Biotech closes Largest Series A Fundraising of 2017 So Far

Breath Therapeutics has raised €43.5M that will be used to finalize development and launch a therapy to improve survival in lung transplant patients. Sofinnova Partners, one of the top biotech VCs in Europe, and the Belgian Gimv have co-led the Series A round of Breath Therapeutics, a German company focusing on treating pulmonary orphan indications. […]

March 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 7 Mar 2017

UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO

UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […]

March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Mar 2017

Meet the Finnish Bioartist using Yeast to Create Vanishing Photographs

Johanna Rotko creates living art with yeast to explore the perishableness of matter and how we interact with nature around us. Johanna Rotko is a visual artist and photographer based in Kotka, Finland, that decided to explore alternative photographic methods. The result were yeastograms, living images made with yeast on petri dishes that disappear over […]

March 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

“In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality”

France Closes in on an HIV Cure by Detecting Cells with Dormant Viruses

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Huge Successful €103M IPO for the Next European Leader in Bioplastics

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

Spain’s Biotech Ecosystem is Starting to Rise! Meet the Revolution’s Leaders

You Can Watch Fleming’s Original Penicillin Culture in Oxford!

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

German Biotech closes Largest Series A Fundraising of 2017 So Far

UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO

Meet the Finnish Bioartist using Yeast to Create Vanishing Photographs

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!